Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC

xlomafota13 shared this article with you from Inoreader Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC Via Association française pour l'étude du cancer Bull Cancer. 2021 Feb 20:S0007-4551(21)00040-0. doi: 10.1016/j.bulcan.2021.01.005. Online ahead of print. NO ABSTRACT PMID:33622569 | DOI:10.1016/j.bulcan.2021.01.005 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.